Radient Pharmaceuticals Corporation fka RXPC

[guardiangel]

Radient Is Being Restructured by A Reverse Merger

Uni-Pharma Part 3 - Global Cancer Diagnostics Part 1
April 29, 2015

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113192928

Uni-Pharma Part 2 April 28, 2015

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113155567

Uni-Pharma Part 1 April 27, 2015

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113119285


Conclusion: April 26, 2015

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113104999

Part 1 April 20, 2015

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=112893006


Part 2 April 21, 2015

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=112930694


Part 3 April 22, 2015

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=112973321

Part 4 April 23, 2015

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113014648

Part 5 April 24, 2015 Rebuttals

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113056841

Part 6 April 25, 2015 Rebuttals

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113091753

All Roads Lead To Taipei,Taiwan Uni-Pharma Partnering with Global cancer Diagnostics to Manufacture and distribute Onko-Sure Overseas.


In this section we will "Clarify" the Alternative Hypothesis considering Uni-Pharma reverse merging with Radient Shell and why we came to the conclusion that it was not a valid hypothesis.

We played the "And" game to get a response and we did..Welcome back GS. You were 50 per cent correct when you said.

"The UNI Agreement terminated when the patent expired."

"And who cares anyway -- the royalty payment was only $200,000 per year."

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113200055

Do you really believe the June 6, 2013 agreement between AMDL Diagnostics Inc. and Uni-Pharma was consummated? We believe it was just a smoke screen.. Here is the agreement between AMDL Diagnostics Inc. and Uni-Pharma. We believe the agreement was between Uni-Pharma and AMDL Diagnostics Inc. because it was not filed in an 8-K. The agreement gave Uni=Pharma exclusive rights in Taiwan.

Radient Pharmaceuticals Enters Distribution Agreement With Uni Pharma for Onko-Sure Sales in Taiwan.......8/4/2011

"announced it has entered into an exclusive distribution agreement with Taiwan-based Uni Pharma, Co. Ltd. Uni Pharma will import, market, and sell Onko-Sure® in the Taiwanese market."

http://www.devicespace.com/news_story.aspx?StoryID=229172


As per the previous agreement, UniPharma had the exclusive right to distribute Radient's cancer test in Taiwan.In the extended distribution agreement it included Singapore, Honk Kong, and Maccau, but doesn't mention it as being exclusive..In the June 6, 2013 agreement Singapore, Hong Knong were listed.The territory left out was Maccau.


Radient expands distribution agreement with UniPharma

22 December 2011

The expanded distribution agreement includes Singapore, Hong Kong and Macau.

This is why GS was only 50 percent correct when he stated that the "The UNI Agreement terminated when the patent expired."The agreement from June 6, 2013 would have terminated but not the August 4, 2011 agreement. We have no idea what was in that agreement,except it had to have a confidentiality and non-compete clause along with a licensing fee and no royalties. In the 2013 agreement it states..
(excepting Taiwan which remains exclusive per UNI-RXPC exclusive distribution agreement) ..This means that the exclusive distributorship from 2011 is still in force and not affected by patents expiring. The 2013 agreement was a smoke screen.

This License Agreement (the “Agreement”), which shall be effective as of June 6, 2013, is by and between Uni Pharma Co., Ltd., a Taipei, Taiwan limited liability company (“UNI”) and Radient Pharmaceuticals Corporation (including its subsidiary AMDL Diagnostics Inc.) a Delaware incorporated United States company (“RXPC”).

Whereas, UNI wishes to hold a non-exclusive 5 year license (excepting Taiwan which remains exclusive per UNI-RXPC exclusive distribution agreement) to RXPC’s Onko-Sure and DR-70 cancer blood test kits (the “Tests”), procedures, analyses, data, know how, manufacturing, manufacturing processes, components, trademarks and intellectual property identified in Exhibit A (the “Intellectual Property”).

http://www.sec.gov/Archives/edgar/data/838879/000121390013003078/f8k061113ex10i_radientpharm.htm

The 2011 Agreement between AMDL Diagnostics Inc. and Uni=Pharma

http://www.devicespace.com/news_story.aspx?StoryID=229172

Run Said:

"Clarification on Uni
How do we know that Uni paid a royalty 3 days after the patent expired last June? Did I miss something?"

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113195445

Run..Did you really think Uni=Pharma would sign an agreement and pay 100,000 dollars for a period of one year? They knew the patent pending would not be approved. Uni-Pharma is witing for William Gartner's patent protected cancer tests and the reverse merger. Even If they had signed the agreement the royalties could not be enforced legally by Radient after the patents expired..So radient would be foolish to have entered that agreement..A smoke screen my friend you understand.... The agreement from 2011 that is still in force can get around that stipulation by making it a license fee instead..

http://www.extendedarticle.com/Newsletters/IIP/2013/IIPye13/IIPye132.html

DC Said:

"GA, I have a question on a recent posting of yours regarding the upcoming Radient Pharmaceuticals/Provista reverse merger. You stated:"

"We believe the GCDX/Bertech PR was a smoke screen. Bertech has not shown news on their web site since 2013 and appears to be dormant. We know from the LSA between Radient and Provista Diagnostics it limits PDX to commercialize Dr-70 tests in the USA market only. So the Canadian company distributorship seems to not fit in the equation."

True the LSA between Provista Diagnostics and Radient would not suffice..Because it is for the USA only.

http://finance.yahoo.com/news/Radient-Pharmaceuticals-iw-331200218.html

But this one is on a global basis..


Radient Pharmaceuticals and Provista Life Sciences Announce New Blood Test for Lung Cancer
Marketwired Radient Pharmaceuticals Corporation
October 13, 2010

"For additional information on Radient Pharmaceuticals, ADI and its portfolio of products."

The agreement with Provista Life Sciences is between AMDL Diagnostics Inc. Here is the connection..This is why William claimed he had no connection with Radient on a business and personal basis as the alleged email claims because he was connected with AMDL Diagnostics and not Radient per the collaboration of the LC Sentinel Lung Cancer Test.

5/4/2010

TUSTIN, CA--(Marketwire - May 04, 2010) - Through its US-based subsidiary AMDL Diagnostics Inc., Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) announced today diagnostics development and commercialization firm Provista Life Sciences LLC (PLS) has independently validated Radient Pharmaceuticals' Onko-Sure in vitro diagnostic (IVD) cancer test as a potential screening tool for breast cancer detection.

http://www.biospace.com/News/provista-life-sciences-llc-provides-independent/179261

DC Said:

"Its one thing for a company to withhold information regarding the Reverse Merger until they are publicly ready, but an entirely different phenomena to intentionally throw people off the Right Trail with false breadcrumbs. Perhaps the truth lies in between the two extremes somewhere."

We believe sometimes you have to throw people off the trail. William claims he sold his LC Sentinel Lung Cancer Test to Provista Diagnostics Inc. According to some here PDx took it off their pipeline, therefore William must not have sold it to Provista Diagnostics.. We believe William took the technology and placed it in his Global Cancer Diagnostics Corporation to keep it separate from the plans he had with the Lympro test and Amarantus...Below it states that PLS/Memory was a subsidiary of Amarantus.

"As of April 29, 2014, Memory Dx, LLC operates as a subsidiary of Amarantus Bioscience Holdings, Inc."

http://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=30028050

But Amarantus only considers them a Partner.

http://www.amarantus.com/about/partners

In the LSA between Radient and Provists Diagnostics it mentions the lung cancer test.

http://finance.yahoo.com/news/Radient-Pharmaceuticals-iw-331200218.html

DC Said:

"Do you feel that part of the ongoing process regarding the upcoming Provista/Radient reverse merger involves intentionally misleading the public?"

Not the public in general, but the competition most likely..

We will discuss our next Alternative Hypothesis..Global Cancer Diagnostics merging into the Radient Shell.

Interesting Read:

http://www.lexisnexis.com/legalnewsroom/corporate/b/blog/archive/2014/12/19/insolvent-company-directors-duties-to-creditors-under-delaware-law.aspx

This link is just one of the reasons William and GCDX will utilize the cheap labor to manufacture Onko_Sure in Taiwan through Uni-Pharma's manufacturer partner in Taiwan, Pharmagene. Manufacturing Onko-Sure in Taiwan and selling it in the global markets will bypass the AHA device tax.


http://www.irs.gov/uac/Medical-Device-Excise-Tax:-Frequently-Asked-Questions